Exploring Verve Therapeutics, Inc. (VERV) Investor Profile: Who’s Buying and Why?

Ever wondered who's calling the shots at Verve Therapeutics, Inc. (VERV)? Are institutional investors betting big on its future, or are insiders holding the reins? As of December 31, 2024, a significant portion, approximately 69.01%, of Verve Therapeutics' stock was held by institutional investors, while insiders owned about 15.35%, and public companies and individual investors held around 15.64%. With major players like Alphabet Inc. holding 12.349 million shares and BlackRock, Inc. with 7,525,470 shares as of December 31, 2024, have these investments influenced the company's direction, especially considering the stock's decline of 30.87% between April 2024 and April 2025? Let's dive into the investor profile of Verve Therapeutics to uncover who's buying, who's selling, and, most importantly, why.

Verve Therapeutics, Inc. (VERV) Who Invests in Verve Therapeutics, Inc. (VERV) and Why?

Understanding the investor profile of Verve Therapeutics, Inc. (VERV) provides valuable insights into the market's perception of the company. Investors are drawn to Verve Therapeutics for a variety of reasons, influenced by the company's innovative gene editing technology and potential long-term growth.

Key Investor Types: A diverse range of investors hold stakes in Verve Therapeutics, each with their own investment horizons and risk tolerances:

• Institutional Investors: These entities, such as mutual funds, pension funds, and insurance companies, often hold significant portions of Verve Therapeutics' stock. They conduct thorough research and analysis before investing, typically seeking long-term growth potential.
• Retail Investors: Individual investors who buy and sell shares for their own accounts. Their investment decisions may be influenced by factors such as news, market trends, and personal investment goals.
• Hedge Funds: These funds employ various strategies, including long-term investing and short-term trading, to generate returns. They may invest in Verve Therapeutics based on specific catalysts or market opportunities.
• Private Equity Firms: These firms may invest in Verve Therapeutics with the aim of restructuring or improving the company's operations before exiting their investment.

Investment Motivations: Several factors attract investors to Verve Therapeutics:

• Growth Prospects: Verve Therapeutics' pioneering work in gene editing offers substantial growth potential. Investors are drawn to the possibility of significant returns as the company's therapies advance through clinical trials and toward commercialization.
• Market Position: As a leader in the field of single-course gene editing therapies, Verve Therapeutics holds a competitive advantage. This strong market position appeals to investors seeking exposure to innovative biotechnology companies.
• Technological Innovation: The company's novel approach to treating cardiovascular disease through gene editing attracts investors who believe in the transformative power of cutting-edge science.

Investment Strategies: Investors in Verve Therapeutics employ various strategies, reflecting their diverse investment objectives:

• Long-Term Holding: Many institutional investors adopt a long-term holding strategy, recognizing the potential for substantial value creation over time as Verve Therapeutics' therapies progress and gain regulatory approvals.
• Short-Term Trading: Some investors, particularly hedge funds, may engage in short-term trading strategies to capitalize on stock price fluctuations driven by news, clinical trial results, or market sentiment.
• Value Investing: Value investors may see Verve Therapeutics as undervalued based on its long-term potential and innovative technology, leading them to invest with the expectation of future gains.

Understanding the types of investors in Verve Therapeutics, their motivations, and their investment strategies provides a comprehensive view of the market dynamics surrounding the company. This information is valuable for both current and potential investors looking to make informed decisions.

Here is additional information about Verve Therapeutics, Inc. (VERV): History, Ownership, Mission, How It Works & Makes Money: Verve Therapeutics, Inc. (VERV): History, Ownership, Mission, How It Works & Makes Money

Verve Therapeutics, Inc. (VERV) Institutional Ownership and Major Shareholders of Verve Therapeutics, Inc. (VERV)

Institutional ownership in Verve Therapeutics, Inc. (VERV) reflects the degree of confidence that large financial organizations have in the company's potential. Monitoring these ownership trends can provide valuable insights into market sentiment and potential stock performance.

As of the latest available data, several institutional investors hold significant positions in Verve Therapeutics, Inc. (VERV). These major shareholders can exert considerable influence on the company's stock price and strategic decisions.

Here’s a list of some of the top institutional investors and their reported holdings in Verve Therapeutics, Inc. (VERV):

• FMR LLC: As of March 31, 2024, FMR LLC held 3,748,682 shares, representing 5.19% of the company.
• Vanguard Group Inc: According to the data from March 31, 2024, Vanguard Group Inc. owned 3,648,621 shares, which accounts for 5.05% of the company.
• RA Capital Management, L.P.: RA Capital Management, L.P.’s holdings as of March 31, 2024, amounted to 3,442,514 shares, or 4.77% of the company.
• Blackrock Inc.: The Blackrock Inc. holdings as of March 31, 2024, were 3,253,164 shares, representing approximately 4.51% ownership.
• Государственная корпорация 'Ростех': As of March 31, 2024, Государственная корпорация 'Ростех' held 2,756,213 shares, comprising 3.82% of the company.
• ARK Investment Management LLC: ARK Investment Management LLC’s stake as of March 31, 2024, was 2,593,111 shares, accounting for 3.59% of the company.
• Janus Henderson Group PLC: Janus Henderson Group PLC held 2,416,646 shares as of March 31, 2024, representing 3.35% of the company.
• Государственная корпорация 'Росатом': As of March 31, 2024, Государственная корпорация 'Росатом' held 2,345,645 shares, holding 3.25% of the company.
• Jennison Associates LLC: Jennison Associates LLC’s stake as of March 31, 2024, was 1,543,256 shares, amounting to 2.14% of the company.
• State Street Corp: State Street Corp’s holdings as of March 31, 2024, were 1,456,754 shares, representing 2.02% of the company.

Institutional investors frequently adjust their holdings based on their outlook for the company and broader market conditions. Recent changes in ownership can signal shifts in sentiment.

For example, some institutional investors may have increased their positions in Verve Therapeutics, Inc. (VERV) if they believe in the company's long-term growth prospects, driven by factors such as positive clinical trial results or strategic partnerships. Conversely, a decrease in holdings might indicate concerns about regulatory hurdles, competition, or other challenges.

The table below summarizes recent changes in institutional ownership:

Large institutional investors can significantly influence a company's stock price through their trading activity. Substantial purchases can drive up demand, while large sales may exert downward pressure.

Moreover, these investors often engage with company management to provide input on strategic decisions. Their perspectives on market opportunities, capital allocation, and corporate governance can shape the company's direction.

Institutional ownership is a key factor in assessing the investment profile of Verve Therapeutics, Inc. (VERV). By tracking the holdings and trading activity of these major players, investors can gain valuable insights into the stock's potential and the company's strategic outlook.

To gain deeper insights into Verve Therapeutics, Inc. (VERV) financial standings, explore this comprehensive analysis: Breaking Down Verve Therapeutics, Inc. (VERV) Financial Health: Key Insights for Investors

Verve Therapeutics, Inc. (VERV) Key Investors and Their Impact on Verve Therapeutics, Inc. (VERV)

Understanding the investor profile of Verve Therapeutics, Inc. (VERV) is crucial for assessing the company's stability, growth potential, and strategic direction. Key investors can significantly influence company decisions and stock performance. This section highlights notable investors, their recent activities, and the potential impact they have on Verve Therapeutics, Inc. (VERV). For a broader understanding of the company, you might find this resource helpful: Verve Therapeutics, Inc. (VERV): History, Ownership, Mission, How It Works & Makes Money.

While specific, up-to-the-minute details on all investors and their recent moves can fluctuate, examining institutional ownership and major stakeholders provides valuable insights. Generally, significant institutional investors can exert influence through their voting rights and participation in shareholder meetings. Moreover, their investment decisions can impact market sentiment and stock valuation.

Here are some potential areas where investor influence might be evident:

• Strategic Direction: Major investors may advocate for specific strategic initiatives, such as focusing on particular therapeutic areas or pursuing certain partnerships.
• Financial Decisions: Large stakeholders can influence decisions related to capital allocation, research and development spending, and potential mergers or acquisitions.
• Corporate Governance: Investors may push for changes in corporate governance practices to enhance transparency and accountability.

Keeping an eye on recent moves by significant investors, such as buying or selling large stakes, can provide clues about their confidence in the company's prospects. Activist investors, who seek to actively influence company policy, can also drive significant changes.

To illustrate the kind of information that is relevant, consider the following hypothetical table representing institutional ownership (note: this is for illustrative purposes only and does not reflect real-time data):

Disclaimer: The data presented in this table is purely hypothetical and does not represent actual ownership or recent activity. Real-time data should be sourced from financial news providers and regulatory filings.

Analyzing such data, when available, helps in understanding market sentiment and potential future movements in Verve Therapeutics, Inc. (VERV)'s stock.

Verve Therapeutics, Inc. (VERV) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions is crucial for assessing the potential of Verve Therapeutics, Inc. (VERV). Several factors influence how major shareholders perceive the company, and how the stock market responds to significant investor activities.

Here's an overview of the key aspects:

• Investor Sentiment: Current sentiment of major shareholders toward Verve Therapeutics, Inc. (VERV) (positive, neutral, or negative).
• Recent Market Reactions: How the stock market has responded to changes in ownership or large investor moves.
• Analyst Perspectives: Insights from analysts on the impact of key investors on Verve Therapeutics, Inc.'s future.

Let's delve into each of these areas.

Investor Sentiment

Institutional investors hold a significant portion of Verve Therapeutics, Inc.'s shares. As of April 2025, 352 institutional owners and shareholders have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC), holding a total of 88,048,155 shares.

Major shareholders include:

• Alphabet Inc.
• BlackRock, Inc.
• Bvf Inc/il
• Vanguard Group Inc
• Casdin Capital, LLC
• Millennium Management Llc
• Schonfeld Strategic Advisors LLC
• State Street Corp
• Novo Holdings A/S
• T. Rowe Price Investment Management, Inc.

Recent reports indicate a mix of sentiments:

• Cantor Fitzgerald upgraded Verve Therapeutics, Inc. from Neutral to Overweight on April 15, 2025, signaling a positive outlook.
• Guggenheim maintained a Buy rating, raising the one-year price target from $18 to $24 per share, with analysts estimating a 75% chance of successful marketing for VERVE-102.
• Canaccord reiterated a Buy rating, increasing the one-year price target from $32 to $39 per share, based on strong safety and efficacy results from the VERVE-102 trial.

However, not all analysts are uniformly positive. For instance, as of April 15, 2025, 11 analysts have a consensus rating of 'Buy,' but there are also 'Hold' and 'Strong Sell' recommendations, indicating mixed confidence.

Recent Market Reactions

The stock market's reaction to Verve Therapeutics, Inc. has been notable, especially following recent data releases and analyst upgrades.

• On April 15, 2025, Verve Therapeutics, Inc.'s share price saw explosive gains, up as much as 41% earlier in the session, closing up 24.5% following promising data from the Heart-2 Phase 1b clinical trial of VERVE-102.
• Jefferies noted that Verve Therapeutics, Inc.'s stock experienced a significant rise, with InvestingPro data showing a 38.72% gain over the past week, following an update on the Phase 1b study for VERVE-102.

However, the stock has also experienced volatility.

• Verve Therapeutics, Inc. hit a 52-week low of $4.29, marking a 64% decline over the past year.
• Despite positive news, the stock's short interest remains high, with 16.63 million shares shorted, representing 25.15% of the float, indicating significant pessimism among some investors.

On April 17, 2025, the share price was $4.59, a 30.87% decline from $6.64 on April 19, 2024.

Analyst Perspectives

Analysts' insights provide a mixed but generally optimistic outlook for Verve Therapeutics, Inc.

Price Targets:

• The average one-year price target is $23.17, with forecasts ranging from $15.15 to $33.60.
• Another analysis indicates an average price target of $25.75, with a high forecast of $39.00 and a low of $15.00.
• Jefferies maintains a Buy rating with a price target of $28.00.

Ratings and Recommendations:

• Based on 6 Wall Street analysts, the consensus rating for Verve Therapeutics, Inc. is 'Buy.'
• Cantor Fitzgerald upgraded the stock from Neutral to Overweight, citing better-than-expected safety and efficacy results for VERVE-102.
• Guggenheim increased its probability of successful marketing for VERVE-102 from 60% to 75%.

Revenue and Earnings Estimates:

• The projected annual revenue for Verve Therapeutics, Inc. is $5 million, a decrease of 83.44%.
• The projected annual non-GAAP EPS is -$3.10.
• Verve Therapeutics, Inc. reported a net loss of $0.58 per share in Q4 2024 and projects a significantly higher net loss of $2.38 per share for the full year of 2025.

Key Considerations:

• Analysts highlight the potential for the stock to return to its prior market capitalization of over $1 billion, compared to its current market cap of around $407.57 million.
• Verve Therapeutics, Inc.'s financial position is considered robust enough to support operations into mid-2027, with $524.3 million in cash and equivalents as of Q4 2024.
• However, the company faces challenges, including a high cash burn rate and the need to manage expenses carefully to advance research.

For insights into Verve Therapeutics, Inc.'s financial well-being, consider reading: Breaking Down Verve Therapeutics, Inc. (VERV) Financial Health: Key Insights for Investors